Fundies.
Français

Opérations des initiés

EDGAR

Immunome, Inc.

Opérations déclarées par les administrateurs, dirigeants et détenteurs de plus de 10 % sur les formulaires 3, 4 et 5 de la SEC, lues dans le XML de chaque dépôt. Les codes et leur libellé sont ceux de la SEC.

Le formulaire 4 doit être déposé dans les deux jours ouvrables suivant l’opération ; les plus récentes peuvent donc ne pas encore être déposées.

Période : opérations datées du 15 nov. 2025 ou après.

Achats sur le marché (code P)
11 opérations, 111 468 actions
Somme actions × prix par action : 2 305 989,79
Ventes sur le marché (code S)
28 opérations, 1 228 648 actions
Somme actions × prix par action : 27 508 460,88

Les totaux additionnent les opérations déposées listées ; ils comptent ce qui a été déclaré et ne mesurent aucune direction.

Affichage de 1 à 50 sur 86

Opérations des initiés, les plus récentes d’abord, telles que déposées sur les formulaires 3, 4 et 5 de la SEC
DateDéclarantCodeAcquis ou cédéActionsPrix par action, tel que déposéValeur (calculée)Actions détenues aprèsDirecte ou indirecteCase de la règle 10b5-1NotesSource
11 sept. 2026 Déposé le 15 sept. 2026Higgins Jack Officer: Chief Scientific Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock		Acquis (A)18 0001,35
24 300

Calculé : actions × prix par action. Valeur exacte 24300.00.

78 250Directe (D) Oui— Ouvrir le dépôt 0001993684-26-000008 Lu dans le XML du dépôt Contester cette ligne
11 sept. 2026 Déposé le 15 sept. 2026Higgins Jack Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock		Cédé (D)13 20025,32
334 224

Calculé : actions × prix par action. Valeur exacte 334224.00.

65 050Directe (D) Oui
F1
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025.
Ouvrir le dépôt 0001993684-26-000008 Lu dans le XML du dépôt Contester cette ligne
11 sept. 2026 Déposé le 15 sept. 2026Higgins Jack Officer: Chief Scientific Officer
G

Bona fide gift

Common Stock		Cédé (D)8 8000—56 250Directe (D) Oui— Ouvrir le dépôt 0001993684-26-000008 Lu dans le XML du dépôt Contester cette ligne
11 sept. 2026 Déposé le 15 sept. 2026Higgins Jack Officer: Chief Scientific Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Titre dérivé: Employee Stock Option (right to buy) — sous-jacent Common Stock (18 000) — prix d’exercice 1.35		Acquis (A)18 0000—133 840Directe (D) Oui
F3
  • F3 25% of the shares subject to the options vested on May 1, 2023, and one-thirty-sixth (1/36th) of the remaining shares subject to the options vests every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
Ouvrir le dépôt 0001993684-26-000008 Lu dans le XML du dépôt Contester cette ligne
12 août 2026 Déposé le 12 août 2026Barchas Isaac Director
S

Open market or private sale of non-derivative or derivative security

Common Stock		Cédé (D)11 04827,25
301 058

Calculé : actions × prix par action. Valeur exacte 301058.00.

92 211Directe (D) Oui
F5
  • F5 The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 31, 2026.
Ouvrir le dépôt 0001808343-26-000010 Lu dans le XML du dépôt Contester cette ligne
11 août 2026 Déposé le 12 août 2026Barchas Isaac Director
S

Open market or private sale of non-derivative or derivative security

Common Stock		Cédé (D)62 29126,23
1 633 892,93

Calculé : actions × prix par action. Valeur exacte 1633892.93.

0Indirecte (I) See footnoteOui
F1, F4, F3
  • F1 The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC (ABHMC) on March 31, 2026.
  • F4 The weighted average sale price for the transaction report was $26.23, and the range of prices were between $26.00 and $26.48, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • F3 ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
Ouvrir le dépôt 0001808343-26-000010 Lu dans le XML du dépôt Contester cette ligne
10 août 2026 Déposé le 12 août 2026Barchas Isaac Director
S

Open market or private sale of non-derivative or derivative security

Common Stock		Cédé (D)10 12526,07
263 958,75

Calculé : actions × prix par action. Valeur exacte 263958.75.

62 291Indirecte (I) See footnoteOui
F1, F2, F3
  • F1 The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC (ABHMC) on March 31, 2026.
  • F2 The weighted average sale price for the transaction report was $26.07, and the range of prices were between $26.005 and $26.14, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • F3 ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
Ouvrir le dépôt 0001808343-26-000010 Lu dans le XML du dépôt Contester cette ligne
7 août 2026 Déposé le 10 août 2026Barchas Isaac Director
S

Open market or private sale of non-derivative or derivative security

Common Stock		Cédé (D)15 24826,06
397 362,88

Calculé : actions × prix par action. Valeur exacte 397362.88.

72 416Indirecte (I) See footnoteOui
F1, F4, F3
  • F1 The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC (ABHMC) on March 31, 2026.
  • F4 The weighted average sale price for the transaction report was $26.06, and the range of prices were between $26.00 and $26.25, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • F3 ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
Ouvrir le dépôt 0001808343-26-000009 Lu dans le XML du dépôt Contester cette ligne
6 août 2026 Déposé le 10 août 2026Barchas Isaac Director
S

Open market or private sale of non-derivative or derivative security

Common Stock		Cédé (D)20 84026,06
543 090,4

Calculé : actions × prix par action. Valeur exacte 543090.40.

87 664Indirecte (I) See footnoteOui
F1, F2, F3
  • F1 The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC (ABHMC) on March 31, 2026.
  • F2 The weighted average sale price for the transaction report was $26.06, and the range of prices were between $26.00 and $26.3318, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • F3 ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
Ouvrir le dépôt 0001808343-26-000009 Lu dans le XML du dépôt Contester cette ligne
4 août 2026 Déposé le 6 août 2026Horn Kinney Officer: CHIEF BUSINESS OFFICER
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock		Acquis (A)50 36612,92
650 728,72

Calculé : actions × prix par action. Valeur exacte 650728.72.

50 366Directe (D) Oui— Ouvrir le dépôt 0001831215-26-000005 Lu dans le XML du dépôt Contester cette ligne
4 août 2026 Déposé le 6 août 2026Horn Kinney Officer: CHIEF BUSINESS OFFICER
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock		Acquis (A)40 25010,60
426 650

Calculé : actions × prix par action. Valeur exacte 426650.00.

90 616Directe (D) Oui— Ouvrir le dépôt 0001831215-26-000005 Lu dans le XML du dépôt Contester cette ligne
4 août 2026 Déposé le 6 août 2026Horn Kinney Officer: CHIEF BUSINESS OFFICER
S

Open market or private sale of non-derivative or derivative security

Common Stock		Cédé (D)90 61625,09
2 273 555,44

Calculé : actions × prix par action. Valeur exacte 2273555.44.

0Directe (D) Oui
F1, F2
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026.
  • F2 The weighted average sale price for the transaction report was $25.09, and the range of prices were between $25.00 and $25.295, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Ouvrir le dépôt 0001831215-26-000005 Lu dans le XML du dépôt Contester cette ligne
4 août 2026 Déposé le 6 août 2026Horn Kinney Officer: CHIEF BUSINESS OFFICER
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Titre dérivé: Employee Stock Option (right to buy) — sous-jacent Common Stock (50 366) — prix d’exercice 12.92		Cédé (D)50 3660—78 542Directe (D) Oui
F3
  • F3 25% of the shares subject to the option vested on August 9, 2025, and the remaining shares will vest monthly thereafter over three years.
Ouvrir le dépôt 0001831215-26-000005 Lu dans le XML du dépôt Contester cette ligne
4 août 2026 Déposé le 6 août 2026Horn Kinney Officer: CHIEF BUSINESS OFFICER
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Titre dérivé: Employee Stock Option (right to buy) — sous-jacent Common Stock (40 250) — prix d’exercice 10.60		Cédé (D)40 2500—120 750Directe (D) Oui
F4
  • F4 25% of the shares subject to the options vested on July 29, 2026, and the remaining shares will vest monthly thereafter over three years.
Ouvrir le dépôt 0001831215-26-000005 Lu dans le XML du dépôt Contester cette ligne
23 juil. 2026 Déposé le 27 juil. 2026Stoneman Sandra G. Officer: CHIEF LEGAL OFFICER GC
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock		Acquis (A)38 2500—43 805Directe (D) Non
F1
  • F1 Represents the number of shares of the Issuer's common stock (Common Stock) underlying restricted stock units (RSUs). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
Ouvrir le dépôt 0001831144-26-000002 Lu dans le XML du dépôt Contester cette ligne
23 juil. 2026 Déposé le 27 juil. 2026Stoneman Sandra G. Officer: CHIEF LEGAL OFFICER GC
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Titre dérivé: Employee Stock Option (right to buy) — sous-jacent Common Stock (76 500) — prix d’exercice 22.01		Acquis (A)76 5000—76 500Directe (D) Non
F2
  • F2 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
Ouvrir le dépôt 0001831144-26-000002 Lu dans le XML du dépôt Contester cette ligne
23 juil. 2026 Déposé le 27 juil. 2026Tsai Philip Officer: Chief Technical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock		Acquis (A)38 2500—81 550Directe (D) Non
F1
  • F1 Represents the number of shares of the Issuer's common stock (Common Stock) underlying restricted stock units (RSUs). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
Ouvrir le dépôt 0002026600-26-000002 Lu dans le XML du dépôt Contester cette ligne
23 juil. 2026 Déposé le 27 juil. 2026Tsai Philip Officer: Chief Technical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Titre dérivé: Employee Stock Option (right to buy) — sous-jacent Common Stock (76 500) — prix d’exercice 22.01		Acquis (A)76 5000—76 500Directe (D) Non
F2
  • F2 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
Ouvrir le dépôt 0002026600-26-000002 Lu dans le XML du dépôt Contester cette ligne
23 juil. 2026 Déposé le 27 juil. 2026Horn Kinney Officer: CHIEF BUSINESS OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock		Acquis (A)31 2500—31 250Directe (D) Non
F1
  • F1 Represents the number of shares of the Issuer's common stock (Common Stock) underlying restricted stock units (RSUs). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
Ouvrir le dépôt 0001831215-26-000004 Lu dans le XML du dépôt Contester cette ligne
23 juil. 2026 Déposé le 27 juil. 2026Horn Kinney Officer: CHIEF BUSINESS OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Titre dérivé: Employee Stock Option (right to buy) — sous-jacent Common Stock (62 500) — prix d’exercice 22.01		Acquis (A)62 5000—62 500Directe (D) Non
F2
  • F2 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
Ouvrir le dépôt 0001831215-26-000004 Lu dans le XML du dépôt Contester cette ligne
23 juil. 2026 Déposé le 27 juil. 2026Rosett Max Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock		Acquis (A)47 2500—101 287Directe (D) Non
F1
  • F1 Represents the number of shares of the Issuer's common stock (Common Stock) underlying restricted stock units (RSUs). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
Ouvrir le dépôt 0001994071-26-000006 Lu dans le XML du dépôt Contester cette ligne
23 juil. 2026 Déposé le 27 juil. 2026Rosett Max Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Titre dérivé: Employee Stock Option (right to buy) — sous-jacent Common Stock (94 500) — prix d’exercice 22.01		Acquis (A)94 5000—94 500Directe (D) Non
F2
  • F2 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
Ouvrir le dépôt 0001994071-26-000006 Lu dans le XML du dépôt Contester cette ligne
23 juil. 2026 Déposé le 27 juil. 2026Lechleider Robert Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock		Acquis (A)54 0000—69 805Directe (D) Non
F1
  • F1 Represents the number of shares of the Issuer's common stock (Common Stock) underlying restricted stock units (RSUs). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
Ouvrir le dépôt 0001997584-26-000006 Lu dans le XML du dépôt Contester cette ligne
23 juil. 2026 Déposé le 27 juil. 2026Lechleider Robert Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Titre dérivé: Employee Stock Option (right to buy) — sous-jacent Common Stock (108 000) — prix d’exercice 22.01		Acquis (A)108 0000—108 000Directe (D) Non
F2
  • F2 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
Ouvrir le dépôt 0001997584-26-000006 Lu dans le XML du dépôt Contester cette ligne
23 juil. 2026 Déposé le 27 juil. 2026SIEGALL CLAY B Director · Officer: President and CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock		Acquis (A)180 0000—870 704Directe (D) Non
F1
  • F1 Represents the number of shares of the Issuer's common stock (Common Stock) underlying restricted stock units (RSUs). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
Ouvrir le dépôt 0001167496-26-000005 Lu dans le XML du dépôt Contester cette ligne
23 juil. 2026 Déposé le 27 juil. 2026SIEGALL CLAY B Director · Officer: President and CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Titre dérivé: Employee Stock Option (right to buy) — sous-jacent Common Stock (360 000) — prix d’exercice 22.01		Acquis (A)360 0000—360 000Directe (D) Non
F2
  • F2 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
Ouvrir le dépôt 0001167496-26-000005 Lu dans le XML du dépôt Contester cette ligne
23 juil. 2026 Déposé le 27 juil. 2026Higgins Jack Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock		Acquis (A)38 2500—60 250Directe (D) Non
F1
  • F1 Represents the number of shares of the Issuer's common stock (Common Stock) underlying restricted stock units (RSUs). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
Ouvrir le dépôt 0001993684-26-000006 Lu dans le XML du dépôt Contester cette ligne
23 juil. 2026 Déposé le 27 juil. 2026Higgins Jack Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Titre dérivé: Employee Stock Option (right to buy) — sous-jacent Common Stock (76 500) — prix d’exercice 22.01		Acquis (A)76 5000—76 500Directe (D) Non
F3
  • F3 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
Ouvrir le dépôt 0001993684-26-000006 Lu dans le XML du dépôt Contester cette ligne
7 juil. 2026 Déposé le 9 juil. 2026Horn Kinney Officer: CHIEF BUSINESS OFFICER
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock		Acquis (A)1 09212,92
14 108,64

Calculé : actions × prix par action. Valeur exacte 14108.64.

1 092Directe (D) Oui— Ouvrir le dépôt 0001831215-26-000002 Lu dans le XML du dépôt Contester cette ligne
7 juil. 2026 Déposé le 9 juil. 2026Horn Kinney Officer: CHIEF BUSINESS OFFICER
S

Open market or private sale of non-derivative or derivative security

Common Stock		Cédé (D)1 09225
27 300

Calculé : actions × prix par action. Valeur exacte 27300.

0Directe (D) Oui
F1
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026.
Ouvrir le dépôt 0001831215-26-000002 Lu dans le XML du dépôt Contester cette ligne
7 juil. 2026 Déposé le 9 juil. 2026Horn Kinney Officer: CHIEF BUSINESS OFFICER
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Titre dérivé: Employee Stock Option (right to buy) — sous-jacent Common Stock (1 092) — prix d’exercice 12.92		Cédé (D)1 0920—128 908Directe (D) Oui
F2
  • F2 25% of the shares subject to the option vested on August 9, 2025, and the remaining shares will vest monthly thereafter over three years.
Ouvrir le dépôt 0001831215-26-000002 Lu dans le XML du dépôt Contester cette ligne
7 juil. 2026 Déposé le 7 juil. 2026Barchas Isaac Director
S

Open market or private sale of non-derivative or derivative security

Common Stock		Cédé (D)16 90624,20
409 125,2

Calculé : actions × prix par action. Valeur exacte 409125.20.

108 504Indirecte (I) See footnoteOui
F1, F4, F3
  • F1 The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC (ABHMC) on March 31, 2026.
  • F4 The weighted average sale price for the transaction report was $24.20, and the range of prices were between $24.00 and $24.58, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • F3 ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
Ouvrir le dépôt 0001808343-26-000007 Lu dans le XML du dépôt Contester cette ligne
6 juil. 2026 Déposé le 7 juil. 2026Barchas Isaac Director
S

Open market or private sale of non-derivative or derivative security

Common Stock		Cédé (D)83 09424,11
2 003 396,34

Calculé : actions × prix par action. Valeur exacte 2003396.34.

125 410Indirecte (I) See footnoteOui
F1, F2, F3
  • F1 The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC (ABHMC) on March 31, 2026.
  • F2 The weighted average sale price for the transaction report was $24.11, and the range of prices were between $24.00 and $24.29, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • F3 ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
Ouvrir le dépôt 0001808343-26-000007 Lu dans le XML du dépôt Contester cette ligne
2 juil. 2026 Déposé le 7 juil. 2026Lechleider Robert Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock		Acquis (A)55 0008,73
480 150

Calculé : actions × prix par action. Valeur exacte 480150.00.

70 805Directe (D) Oui— Ouvrir le dépôt 0001997584-26-000004 Lu dans le XML du dépôt Contester cette ligne
2 juil. 2026 Déposé le 7 juil. 2026Lechleider Robert Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock		Cédé (D)22 71421,95
498 572,3

Calculé : actions × prix par action. Valeur exacte 498572.30.

48 091Directe (D) Oui
F1, F2
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2026.
  • F2 The weighted average sale price for the transaction report was $21.95, and the range of prices were between $21.26 and $22.25, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Ouvrir le dépôt 0001997584-26-000004 Lu dans le XML du dépôt Contester cette ligne
2 juil. 2026 Déposé le 7 juil. 2026Lechleider Robert Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock		Cédé (D)16 21422,76
369 030,64

Calculé : actions × prix par action. Valeur exacte 369030.64.

31 877Directe (D) Oui
F1, F3
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2026.
  • F3 The weighted average sale price for the transaction report was $22.76, and the range of prices were between $22.26 and $23.25, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Ouvrir le dépôt 0001997584-26-000004 Lu dans le XML du dépôt Contester cette ligne
2 juil. 2026 Déposé le 7 juil. 2026Lechleider Robert Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock		Cédé (D)16 07223,44
376 727,68

Calculé : actions × prix par action. Valeur exacte 376727.68.

15 805Directe (D) Oui
F1, F4
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2026.
  • F4 The weighted average sale price for the transaction report was $23.44, and the range of prices were between $23.26 and $23.67, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Ouvrir le dépôt 0001997584-26-000004 Lu dans le XML du dépôt Contester cette ligne
2 juil. 2026 Déposé le 7 juil. 2026Lechleider Robert Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Titre dérivé: Employee Stock Option (right to buy) — sous-jacent Common Stock (55 000) — prix d’exercice 8.73		Cédé (D)55 0000—290 000Directe (D) Oui
F5
  • F5 25% of the shares subject to the option vested on October 16, 2024, and the remaining shares will vest monthly thereafter over three years.
Ouvrir le dépôt 0001997584-26-000004 Lu dans le XML du dépôt Contester cette ligne
2 juil. 2026 Déposé le 2 juil. 2026Barchas Isaac Director
S

Open market or private sale of non-derivative or derivative security

Common Stock		Cédé (D)75 66522,35
1 691 112,75

Calculé : actions × prix par action. Valeur exacte 1691112.75.

232 839Indirecte (I) See footnoteOui
F1, F6, F7
  • F1 The reported sale of these shares occurred automatically pursuant to Rule 10b5-1 trading plans adopted by ABHMC II LLC (ABHMC) and Arsenal Bridge Venture II-B LLC (ABV II-B), each on March 31, 2026.
  • F6 The weighted average sale price for the transaction report was $22.35, and the range of prices were between $22.015 and $23.015, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • F7 ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
Ouvrir le dépôt 0001808343-26-000005 Lu dans le XML du dépôt Contester cette ligne
2 juil. 2026 Déposé le 2 juil. 2026Barchas Isaac Director
S

Open market or private sale of non-derivative or derivative security

Common Stock		Cédé (D)24 33523,33
567 735,55

Calculé : actions × prix par action. Valeur exacte 567735.55.

208 504Indirecte (I) See footnoteOui
F1, F8, F7
  • F1 The reported sale of these shares occurred automatically pursuant to Rule 10b5-1 trading plans adopted by ABHMC II LLC (ABHMC) and Arsenal Bridge Venture II-B LLC (ABV II-B), each on March 31, 2026.
  • F8 The weighted average sale price for the transaction report was $23.33, and the range of prices were between $23.03 and $23.67, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • F7 ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
Ouvrir le dépôt 0001808343-26-000005 Lu dans le XML du dépôt Contester cette ligne
30 juin 2026 Déposé le 2 juil. 2026Barchas Isaac Director
S

Open market or private sale of non-derivative or derivative security

Common Stock		Cédé (D)101 05021,12
2 134 176

Calculé : actions × prix par action. Valeur exacte 2134176.00.

308 504Indirecte (I) See footnotesOui
F1, F2, F3, F4, F5
  • F1 The reported sale of these shares occurred automatically pursuant to Rule 10b5-1 trading plans adopted by ABHMC II LLC (ABHMC) and Arsenal Bridge Venture II-B LLC (ABV II-B), each on March 31, 2026.
  • F2 The shares were sold as follows: 100,000 shares were sold by ABHMC and 1,050 shares were sold ABV II-B.
  • F3 The weighted average sale price for the transaction report was $21.12, and the range of prices were between $20.83 and $21.47, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • F4 The shares of Issuer common stock held by the Reporting Person prior to the transaction reported herein reflect pro rata distributions in kind for no additional consideration, effected by each of Arsenal Bridge Venture II LLC (ABV II) and ABV II-B to their respective members, including ABHMC, the managing member of ABV II and ABV II-B. The receipt of such shares by the Reporting Person constituted a change in form of ownership and, therefore, was not required to be reported pursuant to Section 16, including Rule 16a-13. Following this transaction, ABHMC owns the remaining 308,504 shares of Issuer common stock.
  • F5 The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC and is a co-founder and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABV II-B. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
Ouvrir le dépôt 0001808343-26-000005 Lu dans le XML du dépôt Contester cette ligne
25 juin 2026 Déposé le 29 juin 2026Lechleider Robert Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock		Acquis (A)55 0008,73
480 150

Calculé : actions × prix par action. Valeur exacte 480150.00.

70 805Directe (D) Oui— Ouvrir le dépôt 0001997584-26-000002 Lu dans le XML du dépôt Contester cette ligne
25 juin 2026 Déposé le 29 juin 2026Lechleider Robert Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock		Cédé (D)40 58019,56
793 744,8

Calculé : actions × prix par action. Valeur exacte 793744.80.

30 225Directe (D) Oui
F1, F2
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2026.
  • F2 The weighted average sale price for the transaction report was $19.56, and the range of prices were between $19.27 and $20.255, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Ouvrir le dépôt 0001997584-26-000002 Lu dans le XML du dépôt Contester cette ligne
25 juin 2026 Déposé le 29 juin 2026Lechleider Robert Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock		Cédé (D)14 42020,66
297 917,2

Calculé : actions × prix par action. Valeur exacte 297917.20.

15 805Directe (D) Oui
F1, F3
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2026.
  • F3 The weighted average sale price for the transaction report was $20.66, and the range of prices were between $20.275 and $21.02, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Ouvrir le dépôt 0001997584-26-000002 Lu dans le XML du dépôt Contester cette ligne
25 juin 2026 Déposé le 29 juin 2026Lechleider Robert Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Titre dérivé: Employee Stock Option (right to buy) — sous-jacent Common Stock (55 000) — prix d’exercice 8.73		Cédé (D)55 0000—345 000Directe (D) Oui
F4
  • F4 25% of the shares subject to the option vested on October 16, 2024, and the remaining shares will vest monthly thereafter over three years.
Ouvrir le dépôt 0001997584-26-000002 Lu dans le XML du dépôt Contester cette ligne
15 juin 2026 Déposé le 17 juin 2026Rosett Max Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock		Acquis (A)60 0001,05
63 000

Calculé : actions × prix par action. Valeur exacte 63000.00.

114 037Directe (D) Oui— Ouvrir le dépôt 0001994071-26-000004 Lu dans le XML du dépôt Contester cette ligne
15 juin 2026 Déposé le 17 juin 2026Rosett Max Officer: Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock		Cédé (D)60 00018,23
1 093 800

Calculé : actions × prix par action. Valeur exacte 1093800.00.

54 037Directe (D) Oui
F1, F2
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025.
  • F2 The weighted average purchase price for the transaction report was $18.23, and the range of prices were between $17.95 and $18.66, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
Ouvrir le dépôt 0001994071-26-000004 Lu dans le XML du dépôt Contester cette ligne
15 juin 2026 Déposé le 17 juin 2026Rosett Max Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Titre dérivé: Stock Option (right to buy) — sous-jacent Common Stock (60 000) — prix d’exercice 1.05		Cédé (D)60 0000—0Directe (D) Oui
F3
  • F3 The option is fully vested.
Ouvrir le dépôt 0001994071-26-000004 Lu dans le XML du dépôt Contester cette ligne
10 juin 2026 Déposé le 12 juin 2026WAGENHEIM PHILIP Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Titre dérivé: Director Stock Option (right to buy) — sous-jacent Common Stock (9 897) — prix d’exercice 18.16		Acquis (A)9 8970—9 897Directe (D) Non
F1
  • F1 The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Reporting Person's continuous service with the Company on each respective vesting date.
Ouvrir le dépôt 0001405684-26-000003 Lu dans le XML du dépôt Contester cette ligne
10 juin 2026 Déposé le 12 juin 2026BIENAIME JEAN JACQUES Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Titre dérivé: Director Stock Option (right to buy) — sous-jacent Common Stock (9 897) — prix d’exercice 18.16		Acquis (A)9 8970—9 897Directe (D) Non
F1
  • F1 The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Reporting Person's continuous service with the Company on each respective vesting date.
Ouvrir le dépôt 0001221590-26-000018 Lu dans le XML du dépôt Contester cette ligne

Détenteurs institutionnels (formulaire 13F)

Aucune position du formulaire 13F n’est rattachée à cet émetteur dans le magasin. Un détenteur non encore rattaché ou n’ayant pas encore déposé est absent, pas à zéro.

Détenteurs de 5 % (annexes 13D et 13G)

Les annexes déposées au format structuré de la SEC (depuis fin 2024) sont lues ici. Les précédentes sont en texte libre et ne sont pas lues.

Détenteurs de 5 %, événement le plus récent d’abord, tels que déposés
DétenteurPourcentage de la catégorieActions détenuesDate de l’événementFormulaireSource
Vanguard Capital Management Common Stock5.045 725 57809/30/2026 Déposé le 30 oct. 2026SCHEDULE 13GOuvrir le dépôt 0002100119-26-001633 Contester cette ligne
T. Rowe Price Investment Management, Inc. COMMON STOCK17.419 676 88306/30/2026 Déposé le 14 août 2026SCHEDULE 13G/AModification 2Ouvrir le dépôt 0001897612-26-000609 Contester cette ligne
Sirenia Capital Management LP Common Stock, par value $0.0001 per share4.34 832 279,0006/30/2026 Déposé le 14 août 2026SCHEDULE 13G/AModification 1Ouvrir le dépôt 0000919574-26-005205 Contester cette ligne
Alex Silverstein Common Stock, par value $0.0001 per share4.34 832 279,0006/30/2026 Déposé le 14 août 2026SCHEDULE 13G/AModification 1Ouvrir le dépôt 0000919574-26-005205 Contester cette ligne
Sirenia Capital Management LP Common Stock, par value $0.0001 per share6.16 895 000,0003/31/2026 Déposé le 15 mai 2026SCHEDULE 13GOuvrir le dépôt 0000919574-26-003222 Contester cette ligne
Alex Silverstein Common Stock, par value $0.0001 per share6.16 895 000,0003/31/2026 Déposé le 15 mai 2026SCHEDULE 13GOuvrir le dépôt 0000919574-26-003222 Contester cette ligne
T. Rowe Price Investment Management, Inc. COMMON STOCK14.516 364 01103/31/2026 Déposé le 15 mai 2026SCHEDULE 13G/AModification 1Ouvrir le dépôt 0001897612-26-000495 Contester cette ligne
Redmile Group, LLC Common Stock, $0.0001 par value per share4.95 558 885,0003/31/2026 Déposé le 15 mai 2026SCHEDULE 13G/AModification 4Ouvrir le dépôt 0001104659-26-062570 Contester cette ligne
Jeremy C. Green Common Stock, $0.0001 par value per share4.95 558 885,0003/31/2026 Déposé le 15 mai 2026SCHEDULE 13G/AModification 4Ouvrir le dépôt 0001104659-26-062570 Contester cette ligne
Point72 Asset Management, L.P. Common Stock, par value $0.0001 per share00,0003/31/2026 Déposé le 15 mai 2026SCHEDULE 13G/AModification 1Ouvrir le dépôt 0000919574-26-003480 Contester cette ligne
Point72 Capital Advisors, Inc. Common Stock, par value $0.0001 per share00,0003/31/2026 Déposé le 15 mai 2026SCHEDULE 13G/AModification 1Ouvrir le dépôt 0000919574-26-003480 Contester cette ligne
Steven A. Cohen Common Stock, par value $0.0001 per share00,0003/31/2026 Déposé le 15 mai 2026SCHEDULE 13G/AModification 1Ouvrir le dépôt 0000919574-26-003480 Contester cette ligne
The Vanguard Group Common Stock0003/13/2026 Déposé le 26 mars 2026SCHEDULE 13G/AModification 3Ouvrir le dépôt 0000102909-26-000422 Contester cette ligne
Redmile Group, LLC Common Stock, $0.0001 par value per share5.25 718 385,0012/31/2025 Déposé le 17 févr. 2026SCHEDULE 13G/AModification 3Ouvrir le dépôt 0001104659-26-016437 Contester cette ligne
Jeremy C. Green Common Stock, $0.0001 par value per share5.25 718 385,0012/31/2025 Déposé le 17 févr. 2026SCHEDULE 13G/AModification 3Ouvrir le dépôt 0001104659-26-016437 Contester cette ligne
Enavate Sciences GP, LLC Common Stock, par value $0.0001 per share4.34 768 583,0012/18/2025 Déposé le 22 déc. 2025SCHEDULE 13D/AModification 2Ouvrir le dépôt 0001953107-25-000019 Contester cette ligne
Immunome Aggregator, LP Common Stock, par value $0.0001 per share4.34 768 583,0012/18/2025 Déposé le 22 déc. 2025SCHEDULE 13D/AModification 2Ouvrir le dépôt 0001953107-25-000019 Contester cette ligne
T. Rowe Price Investment Management, Inc. COMMON STOCK12.210 644 67410/31/2025 Déposé le 7 nov. 2025SCHEDULE 13GOuvrir le dépôt 0001897612-25-000510 Contester cette ligne
FMR LLC COMMON STOCK15.013 056 709,1109/30/2025 Déposé le 7 oct. 2025SCHEDULE 13G/AModification 1Ouvrir le dépôt 0000315066-25-002307 Contester cette ligne
Abigail P. Johnson COMMON STOCK15.013 056 709,1109/30/2025 Déposé le 7 oct. 2025SCHEDULE 13G/AModification 1Ouvrir le dépôt 0000315066-25-002307 Contester cette ligne
FMR LLC COMMON STOCK7.16 167 666,0006/30/2025 Déposé le 6 août 2025SCHEDULE 13GOuvrir le dépôt 0000315066-25-002061 Contester cette ligne
Abigail P. Johnson COMMON STOCK7.16 167 666,0006/30/2025 Déposé le 6 août 2025SCHEDULE 13GOuvrir le dépôt 0000315066-25-002061 Contester cette ligne
The Vanguard Group Common Stock5.204 524 95206/30/2025 Déposé le 29 juil. 2025SCHEDULE 13GOuvrir le dépôt 0000932471-25-000844 Contester cette ligne

Le pourcentage porte sur la catégorie que nomme le dépôt, tel que l’a déclaré le détenteur. Les membres d’un groupe déclarent chacun les actions du groupe ; les lignes ne s’additionnent donc pas.

Ce qui a été lu

2 024 280 dépôts lus, datés du 14 juin 2004 au 13 nov. 2026 : formulaires 3, 3/A, 4, 4/A, 5, 5/A.

Certaines années peuvent être incomplètes tant que l’archive est en cours de lecture. Une année avec peu de dépôts ici n’affirme pas qu’il y en a eu peu.

Dépôts lus, par année de dépôt
Année de dépôtDépôts lus
20151
2016204 322
2017202 494
2018202 048
2019193 638
2020144 184
2021224 474
202240 015
2023199 811
2024117 969
2025235 520
2026254 026

Les dépôts antérieurs à l’obligation du XML par la SEC sont listés, non extraits.

Retour à Immunome, Inc.